Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for Cancer
Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it has entered into an agreement with Seoul-based MDimune Inc. to apply their nanovesicle technology to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers. Research findings should provide important insights as Caravan continues to advance the development of its proprietary Mini-CAR™ platform for stand-alone therapeutics and whole-cell CAR co-therapies.
“We are pleased to establish this collaboration with MDimune, a developer of bio-extrusion and delivery,” stated Tom Malcolm, Ph.D., CSO and Founder of Caravan Biologix. “Findings from this collaboration will support our mini- CAR-NK CDV program, which focuses on treating primary liver carcinomas and other human diseases.”
Seung Wook Oh, Ph.D., Chief Scientific Officer of MDimune added, “We are thrilled to launch this collaboration with Caravan Biologix. By joining the advanced mini-CAR-NK technology of Caravan and the enormous therapeutic potential of our vesicle technology, we hope to be able to demonstrate that our BioDrone® platform can significantly escalate the therapeutic promise of current CAR-T/NK-based therapies.”
“The signing of this agreement with Caravan Biologix is another important corporate milestone for MDimune. I am very pleased that our highly innovative and detail-oriented analytical approach to produce the highest quality of cell-derived vesicles at low cost has convinced Caravan Biologix to work with us on such an important endeavor to effectively treat patients with solid tumor cancers. It is clear that new solutions are needed to properly address the complexities associated with traditional whole cell CAR therapeutics,” stated Dr. Oh.
About MDimune Inc.
Founded in 2015, MDimune is dedicated to the development of a next-generation drug delivery platform known as BioDrone®. The company aims to provide a new and flexible modality to generate innovative therapeutics that can address the current challenges of cell & gene therapies. Based on cell-derived vesicles (CDVs) obtained from its proprietary extrusion technology, this novel class of drug carriers will enable highly effective drug delivery to various lesions and allow for treatment with minimum side effects and maximum efficacy. The BioDrone® platform technology is patented in the US, Europe, China, Japan, and Korea. BioDrone® Therapeutics Inc. was founded in 2019 in Seattle, WA to facilitate the global business development of BioDrone® platform technology.
About Caravan Biologix, Inc.
Caravan Biologix is a biotechnology company focused on creating novel therapeutic benefits to broad patient populations by addressing the limitations of whole cell chimeric receptor therapeutics. Caravan’s intellectual property protected technology enables it to develop a wide range of delivery and treatment options from gene editors to small molecules. Our allogeneic iPSC-derived mini-CAR™ and mini-VAN™ platforms, that are based on Cell-Derived Vesicles (CDVs), can be rapidly designed, engineered, and manufactured to build our internal pipeline as well as therapeutics for indications of interest to strategic partners. Caravan’s medicines are expected to show superior safety profiles including lower risk for cytokine release syndrome and other adverse immune reactions. Caravan’s approach will significantly reduce the complexity of manufacturing cell-based therapies, enhance blood-brain barrier penetration properties, and improve the targeted delivery of small molecules and other biologics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005157/en/
Contact information
For further information:
Caravan Biologix, Inc.:
Jeff Riley
CEO
+1.917.510.3773
jeff@caravanbio.com
MDimune Inc.
Seung Wook Oh, Ph.D.:
CSO
+82-2-2655-2636
swoh@mdimune.com; Info@biodroneus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Suzano Launches Nature Strategy and Reinforces the Strategic Importance of Biodiversity Conservation to the Business9.12.2025 17:41:00 EET | Press release
Suzano, the world’s largest pulp producer, has launched its Nature Strategy, reaffirming the company's commitment to biodiversity and how it guides decision-making within the business. Suzano's operations depend directly on nature, and the company recognizes that its longevity and ability to innovate are intrinsically linked to the health of ecosystems. Therefore, nature occupies a significant strategic role in the business’ vision. The science-led Nature Strategy, developed in collaboration with IUCN, is guided by the mitigation hierarchy: avoid, reduce, restore and transform. This approach enables the prevention of impacts, the minimization of risks, and the promotion of ecosystem regeneration. With support from IUCN, Suzano has pioneered the use of the STAR metric – a tool that enables the company to map sensitive areas within the territories where it operates, identify endangered species, and set priority actions required to reduce their risk of extinction. Biodiversity monitoring
Winners of the Global Prize for Innovation in Water Announced9.12.2025 17:28:00 EET | Press release
The city of Jeddah today witnessed a landmark global event with the announcement of the winners of the Global Prize for Innovation in Water in its third edition, marking the conclusion of a highly competitive showcase that drew the attention of the international water community. The winners were revealed during the opening ceremony held as part of the fourth edition of the Innovation Driven Water Sustainability Conference (IDWS2025). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209514013/en/ Winners of the Global Prize for Innovation in Water Announced (Photo: AETOSWire) During the ceremony, the names of 14 winners were announced. Their pioneering solutions succeeded in meeting the rigorous criteria set by the international jury panel. With total prizes amounting to 10 million dollars across all stages, the award recognizes exceptional efforts in transforming research ideas into practical, real-world water technologies.
ITA Group Expands Global Event Capabilities With Two European Acquisitions9.12.2025 17:00:00 EET | Press release
ITA Group, a global leader in engagement solutions, is announcing the strategic acquisition of two award-winning European event agencies: C2events, based in West Yorkshire, England, and Daymakers, based in Utrecht, Netherlands. Effective October 31, 2025, these acquisitions significantly expand ITA Group's local presence and event capabilities throughout Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209885574/en/ Back row: Mark Saxby – C2, Executive Director, Brent Vander Waal – ITA Group, CEO; Front row: Sarah Haines – ITA Group, President Event Solutions, Sophie Hopes – C2, Client Services Director, Danielle Gunn – C2, Client Services Director, Cheryl Clarke – C2, Executive Director, Erica Lalk – ITA Group, Director - Global & Event Strategy The dual acquisitions strengthen ITA Group's position as a global events leader, offering current and prospective clients immediate benefits, including: In-region event tea
Andersen Global Strengthens Valuation Capabilities in Asia Pacific with ETC9.12.2025 16:30:00 EET | Press release
Andersen Global continues to expand its presence in Asia Pacific through a Collaboration Agreement with Edmund Tie & Company (ETC), a full-service real estate advisory firm headquartered in Singapore. Established in 1995, ETC delivers valuation and advisory services across the real estate lifecycle, including statutory and corporate valuation, investment advisory, feasibility studies, and property tax advisory. Operating across Singapore, Malaysia, and Thailand, ETC combines deep regional knowledge with international standards to support developers, investors, private and sovereign funds, corporations, REITs, and owners and occupiers. Known for its research-driven approach and integrated service model, the firm helps clients navigate regulatory complexity and optimize asset value. “Our strength lies not just in technical execution, but in helping clients see the full picture—connecting market signals, regulatory shifts, and long-term value drivers,” said Desmond Sim, CEO of ETC. “Colla
Grid Dynamics Signs Strategic Collaboration Agreement with AWS to Advance Data Foundations for Generative AI9.12.2025 16:15:00 EET | Press release
Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) (Grid Dynamics), a premier IT consulting and digital services provider, today announced it has entered into a multi-year strategic collaboration agreement (SCA) with Amazon Web Services (AWS). The agreement focuses on enabling and scaling generative AI journeys for enterprise companies, extending a 15-year relationship between the companies. The collaboration provides Grid Dynamics access to the AWS Data Foundations for Generative AI Program, established to help organizations build the robust, governed, and high-quality data infrastructures required to adopt and scale AI. By combining the AWS suite of cloud-native data and AI services and Grid Dynamics’ deep expertise in data engineering, analytics, and AI/ML, enterprises can accelerate their progress in AI from experimentation to full-scale production. As a recognized AWS Partner with deep technical expertise and proven customer success, Grid Dynamics expects to play a pivotal role in enabli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom